ArticleScientific reports2026
Bio-generated CoO-NPs from Salvia officinalis: a promising tool against ESBL-producing bacteria.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extended-spectrum β-lactamase (ESBL)-producing bacteria pose significant therapeutic challenges, necessitating the development of alternative antimicrobial agents such as metal nanoparticles. Among 58 bacterial isolates from clinical samples at the National Cancer Institute (Cairo, Egypt), eight ESBL-producing strains were identified (six E. coli and two K. pneumoniae) using phenotypic screening and VITEK 2 system, representing preliminary laboratory findings. GC-MS analysis of Salvia officinalis aqueous extract revealed 16 compounds, with rosmarinic acid (20.41%) as the major constituent. The successful green synthesis of cobalt oxide nanoparticles (CoO-NPs) using S. officinalis was confirmed through UV-visible spectroscopy showing a characteristic peak at 520 nm, HRTEM revealing particle sizes of 10-50 nm, and XRD patterns matching the CoO phase. FTIR spectroscopy confirmed the presence of metal-oxygen bonds and surface functionalization. CoO-NPs demonstrated significant antibacterial activity against ESBL-producing isolates with inhibition zones ranging from 24 to 26 mm and MIC values of 0.312-0.625 mg/ml while enhancing the efficacy of several antibiotics, particularly rifampicin, meropenem, and gentamicin. Antioxidant assays revealed free radical scavenging activity with IC50 values of 513.7 µg/mL and 208 µg/mL for DPPH (2,2-diphenyl-1-picrylhydrazyl) and ABTS (2,2'-azino-di-[3-ethylbenzthiazoline sulfonate (6)]), respectively. Cytotoxicity studies against normal cell lines showed dose-dependent effects with IC50 values of 303.526 µg/mL for VERO cells and 253.19 µg/mL for OEC cells, with significant morphological changes observed at 500 µg/mL. These preliminary laboratory findings suggest that S. officinalis-mediated CoO-NPs represent a promising therapeutic agent against ESBL-producing bacteria, offering a balance between antimicrobial efficacy and biological safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.